WHERE WILL YOUR TREATMENT JOURNEY GO?
Discover information and resources for your LUMRYZ treatment experience.
Your Resources
Starting a new treatment is a big step. View or download the resources below for support along the way
Use this tool to help you and your healthcare provider have productive conversations about your narcolepsy and sleep patterns
Titration is a process that may take time
Titration is the process of allowing the body to adjust to a new medicine by starting with the smallest dose—then going up a dose, slowly over time, and possibly going back down a dose, to try and find a stable dose that balances effectiveness and tolerability.
It’s okay to need extra support during your titration period with LUMRYZ
Remember to share all of your treatment experiences with your healthcare provider so they can make adjustments to your dose or discontinue if necessary.
It’s okay to need extra support from your healthcare team during the titration process—and your dedicated Nurse Care Navigator (NCN) is also available for questions about taking LUMRYZ as prescribed.
Listen to your body as you titrate
You and your healthcare provider will work together to make adjustments to your dose based on how you are responding to treatment
The most common side effects reported by adult participants in the clinical trial were nausea, dizziness, bedwetting, headache, and vomiting.
In pediatric patients, the most common side effects include nausea, bedwetting, vomiting, headache, weight decreased, decreased appetite, dizziness, and sleepwalking.
Understanding the safety data of LUMRYZ
In the clinical trial, side effects typically occurred when participants started a new dose. Generally, the side effects then declined over time while staying on the same dose.
Use the chart below to explore how the frequency of side effects changed in the clinical trial
Notice the change in the bars from week to week when titrating.
SIDE EFFECTS OF LUMRYZ OVER TIME
- Nausea
- Vomiting
- Decreased appetite
- Headache
- Dizziness
- Bedwetting
- Anxiety
Participants titrated up a dose every 1-5 weeks for 13 weeks in the clinical trial. It's important to remember that your titration experience may look different based on what is effective and tolerable for you.
Finding a LUMRYZ dose that works with your treatment goals can take time.
Everyone responds to treatment differently
In the clinical trial, some participants saw improvement in their symptoms by week 3 on a 6-g dose, while others saw improvement at week 13 after increasing the dose.*
*The LUMRYZ double-blind, placebo-controlled clinical trial included participants with narcolepsy treated with LUMRYZ (n=107). The results measured at week 3 (n=88), week 8 (n=77), and week 13 (n=69) showed daytime symptom improvement of participants on the 6-g, 7.5-g, and 9-g doses of LUMRYZ, respectively. Individual results may vary.
Want to learn more about the LUMRYZ clinical trial?
It may help to keep track of how you’re feeling
As you progress through treatment with LUMRYZ, you'll want to consider how you feel in the morning and throughout the day.
Keeping a journal can be useful to track how symptoms of excessive daytime sleepiness (EDS) and/or cataplexy may change.
Throughout your treatment, it's important to tell your healthcare provider about any side effects you experience as they may choose to make adjustments to your dose or stop treatment.
You are not alone at any step with LUMRYZ
Your NCN is a phone call away
You can contact your NCN to help you prepare for discussions with your healthcare provider, such as writing down helpful notes to bring to your next treatment check-in.
RYZUP™ Support Services can connect you with your NCN: 1-844-485-7636.
Use this tool to take notes about your sleep for discussion with your healthcare provider.
Everyone's treatment experience is different
Explore these words of inspiration from healthcare providers who prescribe LUMRYZ and a person with narcolepsy
Individuals featured have been compensated by Avadel Pharmaceuticals. Individual results may vary.
“When I explain titration to my patients, I like to describe it as: During the titration process, your dose may be adjusted based on what is effective and tolerable for you. It may take time to notice a difference in your symptoms of EDS or cataplexy.
For some people, adjusting to a new medicine and treatment routine may be challenging—and that’s why I am here to help. Consider writing down your experiences each week so we can discuss them during check-ins.”
–Lewis Kass, MD Sleep Specialist Valley Health System
“I typically ask my patients to check in with me after three weeks. I ask them how they’re feeling when they wake up and throughout the day, and what impact they may start to notice in their symptoms.
Sometimes, we may keep them on the same dose for longer before changing anything—or we may titrate them up or down to a different dose. It is important for patients who start on a 4.5-g dose to know that it may not be their stable dose based on effectiveness and tolerability.
It’s common for patients to experience side effects after titrating to a different dose, which is why I like to check in with my patients about how they’re feeling during the process. And sometimes, it may not be the right treatment.
But overall, the best advice I can give is have patience. Treating narcolepsy isn’t a sprint, it’s a marathon.”
–Michael Strunc, MD Sleep Specialist Children’s Hospital of the King’s Daughters
“When I switched from my twice-nightly oxybate to LUMRYZ, the titration process wasn’t as challenging as I had expected (perhaps because I didn’t know what to expect). I started on the LUMRYZ dose closest to what twice-nightly oxybate I was taking and shared with my doctor how I was feeling and what symptoms I was experiencing. After a few weeks, my doctor then increased my dose and we again discussed how my EDS and cataplexy symptoms were and if I was experiencing any side effects. My doctor adjusted my LUMRYZ dose once and that is the dose I am taking today.”
–Sarah B., living with narcolepsy and treating with LUMRYZ
Frequently Asked Questions
Select a question below to see the answer
If you are ever unclear on next steps with insurance and benefits investigation, finding financial assistance, prescription shipments, or other questions about starting LUMRYZ, you can call your NCN for support.
No, you can remain on your twice-nightly oxybate until the insurance coverage process for your LUMRYZ prescription is complete.
If there is a delay in insurance coverage, you may be eligible for up to 120 days of free LUMRYZ with the Temporary Assistance Program.†
†Applies only to eligible, commercially insured patients.
Your dedicated NCN will help connect you with any financial assistance you may qualify for, including:
Your co-pay could be as little as $0 if you have commercial insurance.‡
Temporary Access Program (TAP) If there is a delay in insurance coverage, you may be eligible for up to 120 days of free LUMRYZ.§
Patient Assistance Program (PAP) Treatment is available free of charge to eligible patients who are uninsured or underinsured.||
You can ask your NCN about available support services at any time during your treatment experience.
‡This offer is valid only for patients who have commercial insurance. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Additional terms and conditions apply. Download the full terms and conditions of the co-pay program.
§Applies only to eligible, commercially insured patients.
||PAP application required. Patient must meet certain financial and other criteria.
With LUMRYZ, you take 1 premeasured packet, once at bedtime. See the full Instructions for Use for how to prepare, shake, and take LUMRYZ.
Watch this video for a step-by-step guide or download the LUMRYZ Dosing Guide for an offline resource.
After following the full Instructions for Use to prepare your LUMRYZ dose, you may notice the mixture does not fully dissolve in water and has a gritty texture with a salty taste.
This is because the unique formulation is designed to release medicine into the body while you sleep—which is what makes LUMRYZ a once-at-bedtime oxybate treatment.
Titration is the process of allowing the body to adjust to a new medicine by starting with the smallest dose—then going up a dose, slowly over time, and possibly going back down a dose to try and find a stable dose that balances effectiveness and tolerability. It may take 3 to 13 weeks for this to occur.
It’s important to share all of your treatment experiences with your healthcare provider during the titration process so you can work together to find the best treatment fit for you.
Everyone responds to treatment differently. In the clinical trial for LUMRYZ, some participants saw significant symptom improvements as early as week 3 while others saw symptom improvements at week 13¶ after titrating to a higher dose.
Consider keeping track of how you are feeling with LUMRYZ in a symptom journal.
¶The LUMRYZ double-blind, placebo-controlled clinical trial included participants with narcolepsy treated with LUMRYZ (n=107). The results measured at week 3 (n=88), week 8 (n=77), and week 13 (n=69) showed daytime symptom improvement of participants on the 6-g, 7.5-g, and 9-g doses of LUMRYZ, respectively. Individual results may vary.
In a clinical trial, the total sleep time did not change from when the trial started to the end of the trial. LUMRYZ participants slept for approximately 7 hours at the beginning and end of the trial.
People with narcolepsy generally sleep the same amount of time at night as people without narcolepsy, but most people with narcolepsy don’t have good quality sleep. Speak to your healthcare provider about your sleep as well as how you feel when you wake up the following day.
The most common side effects reported by adult participants in the clinical trial were nausea, dizziness, bedwetting, headache, and vomiting.
In the clinical trial for LUMRYZ, side effects typically occurred when participants started a new dose. Generally, the side effects then declined over time while staying on the same dose.
The safety of LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy was determined in a well-controlled trial of immediate-release sodium oxybate.
The most common side effects in children include nausea, bedwetting, vomiting, headache, decreased weight, decreased appetite, dizziness, and sleepwalking.
Explore the side effects over time in the clinical trial for LUMRYZ.
